On April 18, 2023, global biopharmaceutical company GSK announced the $2 billion acquisition of late-stage biopharmaceutical company BELLUS Health. Wilson Sonsini Goodrich & Rosati advised BELLUS on patent matters related to the transaction.

Canada-based BELLUS is focused on treating patients suffering from refractory chronic cough (RCC). The company is currently in phase 3 of clinical development for camlipixant, a highly selective P2X3 antagonist, which can be used as a first-line treatment for adult patients with RCC. The company expects regulatory approval launch in 2026.

GSK is paying BELLUS $14.75 per share in cash, which represents a 103 percent premium to the company’s closing stock price on April 17, 2023. The transaction is expected to close by the third quarter of 2023.

The Wilson Sonsini team advising on the patent matters includes Lori Westin, Jim Malecha, and former partner Lee Johnson.

For more information, please see the press release.